Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
David Planchard,Pasi A Jänne,Ying Cheng,James C-H Yang,Noriko Yanagitani,Sang-We Kim,Shunichi Sugawara,Yan Yu,Yun Fan,Sarayut L Geater,Konstantin Laktionov,Chee K Lee,Natalia Valdiviezo,Samreen Ahmed,Jean-Marc Maurel,Igor Andrasina,Jonathan Goldman,Dana Ghiorghiu,Yuri Rukazenkov,Alex Todd,Kunihiko Kobayashi,FLAURA2 Investigators,Juan Cundom,Karina Vera,Monica Casalnuovo,Marcelo Tatangelo,Nicolas Castagneris,Guillermo Streich,Chee Khoon Lee,Paul Mitchell,Brett Hughes,Michael Boyer,Thomas John,Dainik Patel,Gustavo Pinto,Yeni Neron,Rivadavio Oliveira,Juliana de Menezes,Adilson Faccio,Glaucio Bertollo,Gilberto de Castro Jr,Otavio Gampel,Frances Shepherd,Doreen Ezeife,Randeep Sangha,Eugenia Loredo,Cristian Ibarra,Carlos Rojas,Patricio Yanez,Yi Hu,Baoshan Cao,Yuan Chen,Ye Wang,Jialei Wang,Yueyin Pan,Zhigang Han,Bo Shen,Qiming Wang,Meili Sun,Yu Yao,Huiqing Yu,Liyan Jiang,Wenxiu Yao,Jian Fang,Lin Wu,Jie Hu,Rong Wu,Jianya Zhou,Yijiang Huang,Laiyu Liu,Leona Koubkova,Juraj Kultan,Libor Havel,Jaromir Roubec,Maurice Perol,Xavier Quantin,Charlotte Domblides,Hari Goyal,Rohan Bhise,Sumit Goyal,Satheesh Thungappa,Bivas Biswas,Chetan Deshmukh,Hiroshi Kagamu,Yuichi Tambo,Yoshitaka Zenke,Kyoichi Okishio,Terufumi Kato,Kazumi Nishino,Isamu Okamoto,Satoshi Oizumi,Toshiaki Takahashi,Tetsuji Kawamura,Masahiro Seike,Takehito Shukuya,Shoichi Kuyama,Manuel Leiva,Alejandro Figueroa,Vanessa Bermudez,Renzo Alvarez Barreda,Annielyn Beryl Ong-Cornel,Jerry Tan Chun Bing,Rubi Li,May Sabando,Arthur Gregory Lui,Jandre Jomar Alipat,Guia Elena Imelda Ladrera,Nina Karaseva,Artem Poltoratskiy,Elena Matyushina,Evgeniy Fomin,Daniil Stroyakovskiy,Olga Mikheeva,Louis Dupper,Rapoport Bernardo,Myung-Ju Ahn,Ji-Youn Han,Ki Hyeong Lee,Tae Min Kim,Tsung-Ying Yang,Inn- Wen Chong,Po-Hao Feng,James Chih-Hsin Yang,Te-Chun Hsia,Sheng-Hao Lin,Chih-Bin Lin,Virote Sriuranpong,Sarayut Lucien Geater,Busyamas Chewaskulyong,Jarin Chindaprasirt,Thanyanan Reungwetwattana,Kunlatida Maneenil,Teerapat Ungtrakul,Riyaz Shah,Raffaele Califano,Carles Escriu,Huiqi Yang,Pasi Jänne,John Hamm,Ian Anderson,Ali Amjad,Raza Khan,Jhanelle Gray,Eric McGary,Lyudmila Bazhenova,Chao Huang,Anirudha Dasgupta,Ronald Natale,Timothy Burns,Tarek Mekhail,Alexandra Spira,Anthony Van Ho,Melissa Crawley,William Lawler,Anthony Nguyen,Lisa Wang,Xuan Dung Pham,Tho Tran,Quyen Le,Khiem Dang
DOI: https://doi.org/10.1056/NEJMoa2306434
2023-11-23
Abstract:Background: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy. Methods: In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR-mutated (exon 19 deletion or L858R mutation) advanced non-small-cell lung cancer (NSCLC) who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed [500 mg per square meter of body-surface area] plus either cisplatin [75 mg per square meter] or carboplatin [pharmacologically guided dose]) or to receive osimertinib monotherapy (80 mg once daily). The primary end point was investigator-assessed progression-free survival. Response and safety were also assessed. Results: A total of 557 patients underwent randomization. Investigator-assessed progression-free survival was significantly longer in the osimertinib-chemotherapy group than in the osimertinib group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.49 to 0.79; P<0.001). At 24 months, 57% (95% CI, 50 to 63) of the patients in the osimertinib-chemotherapy group and 41% (95% CI, 35 to 47) of those in the osimertinib group were alive and progression-free. Progression-free survival as assessed according to blinded independent central review was consistent with the primary analysis (hazard ratio, 0.62; 95% CI, 0.48 to 0.80). An objective (complete or partial) response was observed in 83% of the patients in the osimertinib-chemotherapy group and in 76% of those in the osimertinib group; the median response duration was 24.0 months (95% CI, 20.9 to 27.8) and 15.3 months (95% CI, 12.7 to 19.4), respectively. The incidence of grade 3 or higher adverse events from any cause was higher with the combination than with monotherapy - a finding driven by known chemotherapy-related adverse events. The safety profile of osimertinib plus pemetrexed and a platinum-based agent was consistent with the established profiles of the individual agents. Conclusions: First-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC. (Funded by AstraZeneca; FLAURA2 ClinicalTrials.gov number, NCT04035486.).